Published in Ren Fail on November 01, 1997
Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int (2001) 2.81
Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int (1997) 2.47
Who provides patients with drug information? Br Med J (Clin Res Ed) (1987) 2.04
Do diabetic patients inject accurate doses of insulin? Diabetes Care (1981) 2.02
Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities. Ann Pharmacother (1997) 1.53
Disruptions in drug therapy in long-term dialysis patients who require hospitalization. Am J Health Syst Pharm (1999) 1.48
Pharmacokinetics of once-daily IP gentamicin in CAPD patients. Perit Dial Int (1997) 1.47
Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis. Perit Dial Int (1995) 1.46
Recovery of S. epidermidis and E. coli from effluent peritoneal dialysate. Perit Dial Int (1991) 1.39
Current status of whole-body counting as a means to detect and quantify previous exposures to radioactive materials. Whole-body Counting Working Group. Health Phys (1991) 1.39
Disinfection of CAPD bag ports. Perit Dial Int (1989) 1.39
Absorption interactions with fluoroquinolones. 1995 update. Drug Saf (1995) 1.12
Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol (1997) 1.05
Vancomycin, red neck syndrome, and fits. Lancet (1985) 0.99
End-stage renal disease: factors affecting referral decisions by family physicians in Canada, the United States, and Britain. Am J Kidney Dis (2001) 0.95
Impulse control disorders in Parkinson's disease: don't set your mind at rest by self-assessments. Eur J Neurol (2015) 0.90
Successful treatment of CAPD peritonitis caused by Neisseria cinerea. Perit Dial Int (1994) 0.90
Continuous ambulatory peritoneal dialysis: a review of its mechanics, advantages, complications, and areas of controversy. Ann Pharmacother (1992) 0.89
Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. J Clin Pharm Ther (1987) 0.89
Intravenous or intraperitoneal vancomycin for the treatment of continuous ambulatory peritoneal dialysis associated gram-positive peritonitis? Nephron (1987) 0.88
Knowledge of hemodialysis and CAPD patients about their prescribed medicines. Clin Nephrol (1990) 0.87
Quinolone-cation interactions: a review. DICP (1991) 0.87
Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int (2001) 0.87
Risk factors for inadequate use of pressurized aerosol inhalers. J Clin Pharm Ther (1988) 0.87
Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1991) 0.87
Comparing medication use in two hemodialysis units against national dialysis databases. Am J Health Syst Pharm (2000) 0.87
A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull (2001) 0.86
Current status of bioassay procedures to detect and quantify previous exposures to radioactive materials. Bioassay Procedures Working Group. Health Phys (1991) 0.86
Intravenous iron products. ANNA J (1999) 0.86
Successful treatment of Aeromonas hydrophila peritoneal dialysis-associated peritonitis using intermittent intraperitoneal gentamicin. Clin Nephrol (1995) 0.86
Complex of aspartate carbamoyltransferase from Escherichia coli with its allosteric inhibitor, cytidine triphosphate: electron density at 5.9-angstroms resolution. Proc Natl Acad Sci U S A (1974) 0.86
Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. J Am Soc Nephrol (2000) 0.85
Stability of iron dextran (DexFerrum) in peritoneal dialysis bags. Perit Dial Int (1999) 0.84
Dosing adjustment of 10 antimicrobials for patients with renal impairment. Ann Pharmacother (1995) 0.84
Significance of self-reported sleep quality (SQ) in chronic kidney disease (CKD): the Renal Research Institute (RRI)-CKD study. Clin Nephrol (2010) 0.84
Pharmacists' perceptions of alternative health approaches--a comparison between U.S. and British pharmacists. J Clin Pharm Ther (1990) 0.84
Pharmacokinetics of intermittent intraperitoneal ceftazidime. Am J Kidney Dis (1999) 0.84
Controlled evaluation of thermal biofeedback in treatment of elevated blood pressure in unmedicated mild hypertension. Biofeedback Self Regul (1996) 0.83
Stability of amphotericin B-lipid complex (Abelcet) in peritoneal dialysis solutions. Perit Dial Int (2000) 0.83
Aortic valve debridement by ultrasonic surgical aspirator in degenerative, aortic valve stenosis: follow-up with Doppler echocardiography. Eur J Cardiothorac Surg (1996) 0.83
Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. Int J Artif Organs (2005) 0.83
Cyclosporine-associated arthralgia. Clin Nephrol (1990) 0.83
Massive and extended rebound of serum lithium concentrations following hemodialysis in two chronic overdose cases. Am J Emerg Med (1998) 0.82
The emergency department care of hemodialysis patients. Clin Nephrol (2002) 0.81
Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. Clin Nephrol (1993) 0.81
Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis (2001) 0.81
Unsuccessful treatment of CAPD peritonitis caused by Alcaligenes xylosoxidans subsp. denitrificans. Ren Fail (1995) 0.81
Correlation of intraperitoneal antibiotic pharmacokinetics and peritoneal membrane transport characteristics. Perit Dial Int (2001) 0.81
Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int (2001) 0.80
Aminoglycoside therapy. Improving patient response and safety. Postgrad Med (1984) 0.79
Red-neck syndrome associated with intraperitoneal vancomycin. Clin Pharm (1990) 0.79
Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP (1991) 0.79
Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord (2011) 0.79
Thermal biofeedback as an effective substitute for sympatholytic medication in moderate hypertension: a failure to replicate. Biofeedback Self Regul (1993) 0.79
Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity. Nephrol Dial Transplant (1996) 0.79
Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. Clin Nephrol (1996) 0.79
Atheroembolic renal disease: association with renal arterial stenosis. Cleve Clin J Med (1989) 0.78
Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis. Clin Pharmacokinet (1990) 0.77
Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int (1999) 0.77
[Comparative studies on driving fitness following hashish consumption and following brief anesthesia]. Med Welt (1971) 0.77
Bioavailability of bumetanide in grossly oedematous patients. Clin Pharmacokinet (1987) 0.77
Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit Dial Int (1995) 0.77
Trends in clinical indicators of care for adult peritoneal dialysis patients in the United States from 1995 to 1997. ESRD Core Indicators Workgroup. Kidney Int (1999) 0.76
Treatment of acute carbamazepine poisoning by hemoperfusion. Am J Emerg Med (1996) 0.76
Peritonitis in automated peritoneal dialysis: antibiotic therapy and pharmacokinetics. Perit Dial Int (2001) 0.76
Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. Ann Pharmacother (1993) 0.76
Prediction of serum vancomycin concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal dialysis patients with peritonitis. Clin Pharmacokinet (1992) 0.76
Exfoliative reaction to vancomycin. Br Med J (Clin Res Ed) (1988) 0.75
Timeliness of medication administration in hemodialysis inpatients: drug use evaluation. Hosp Pharm (1993) 0.75
Stability of erythromycin lactobionate in peritoneal dialysate solutions. Perit Dial Int (1994) 0.75
[Gas chromatographic studies on inflow, distribution and elimination of halothane and penthrane]. Z Prakt Anasth Wiederbeleb Intensivther (1972) 0.75
Patient knowledge of cardio-respiratory drugs. J Clin Pharm Ther (1988) 0.75
Variability in creatinine clearance (CCR) and KT/V due to different methods of calculating volume and CCR. Perit Dial Int (1997) 0.75
Experimental study of balloon-expandable metallic vena caval stents in rabbits. J Vasc Interv Radiol (1994) 0.75
Chemical peritonitis associated with intraperitoneal vancomycin. DICP (1991) 0.75
Effectiveness of theophylline monitoring by the use of serum assays. J Clin Pharm Ther (1988) 0.75
Correlation of whole blood activated partial thromboplastin time and plasma activated partial thromboplastin time in haemodialysis patients. Nephrol Dial Transplant (1996) 0.75
Acute renal failure and hyperkalemia associated with triamterene and indomethacin. Vet Hum Toxicol (1986) 0.75
Interleukin, endotoxin, and tumor necrosis factor in CAPD dialysate. Perit Dial Int (1995) 0.75
Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. J Antimicrob Chemother (1995) 0.75
Low prevalence of vancomycin-resistant Enterococcus in dialysis outpatients with a history of vancomycin use. Perit Dial Int (1997) 0.75
The effect of temperature and glucose concentration on the growth of microorganisms commonly associated with CAPD peritonitis. Perit Dial Int (1995) 0.75
Comment: pharmacy manpower contrast--U.K. Drug Intell Clin Pharm (1986) 0.75
Turbid dialysate effluent and bacterial peritonitis. Clin Nephrol (1991) 0.75
Cost/benefit analysis of aminoglycoside use without a kinetic dosing service. Drug Intell Clin Pharm (1988) 0.75
Plasma growth hormone (GH) responses to growth hormone releasing factor (hp GRF 1-44) in familial GH deficiency. Acta Paediatr Scand (1987) 0.75
Renal transplant patients' knowledge concerning cyclosporine treatment. Clin Nephrol (1991) 0.75
Disposition of intrathecal vancomycin. Drug Intell Clin Pharm (1988) 0.75
Unusual treatment response of a severe dystonia to diphenhydramine. Ann Emerg Med (1987) 0.75
Failure of intraarticular ceftazidime in a patient with Pseudomonas aeruginosa septic arthritis. Drug Intell Clin Pharm (1988) 0.75